Orthobiologics Market Analysis By Product (DBM, Allograft, BMP, Viscosupplementation, Synthetic Bone Substitutes, Stem Cell), By Application (Spinal Fusion, Reconstructive Surgery, Trauma Repair), By End Use, And Segment Forecasts, 2014 - 2025

The global orthobiologics market is expected to reach USD 10.2 billion by 2025, according to a new study by Grand View Research, Inc. The orthobiologics market is predominantly driven by the increasing orthopedic disease and musculoskeletal disease burden globally. Moreover, emerging technological innovations in biomaterials, used in the production of orthobiologics are presumed to accelerate the market demand over the forecast period. These predominantly include modifications in graft designs, advent of recombinant biologic agents, stem cell therapy and cultured tissue scaffolds.

These advancements are accompanied with the benefits such as enhanced biocompatibility, reduced surgical time and smaller incisions. Furthermore, these novel solutions are presumed to efficiently reduce the recurrence of post-operative complications, which in turn is expected to boost the orthobiologics market during the forecast period.

Further Key Findings From the Study Suggest:

In 2015, viscosupplementation accounted for the largest share in the product segment owing to being a cost efficient therapeutic alternative for symptomatic management of osteoarthritis

Spinal fusion held the largest share in the application segment in 2015, owing to presence of third party insurers and reimbursement structure for fusion enhancement products thus triggering growth

In 2015, North America accounted for the dominant share owing to consistent efforts of industry players in promoting awareness pertinent to the orthobiological products resulting in significant rise in adoption rate

Asia Pacific is anticipated to exhibit an exponential CAGR as a consequence of significant surge in healthcare spending and awareness levels with respect to the availability of orthobiologics

The prominent players are consistently indulging into extensive strategies to gain competitive position including regional expansion and mergers & acquisitions to capture a greater market share

For instance, in November 2015, Bioventus acquired BioStructures, a bioabsorbable bone graft developer. This acquisition was carried out to expand orthobiologics product portfolio and grafting solutions in order to expand their market share

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
Chapter 3 Orthobiologics Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.2 Market Driver Analysis
3.3 Market Restraint Analysis
3.4 Penetration & growth prospect mapping
3.5 Orthobiologics - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
Chapter 4 Orthobiologics Market: Product Estimates & Trend Analysis
4.1 Orthobiologics market: Product movement analysis
4.2 Demineralized Bone Matrix (DBM)
4.2.1 DBM market estimates and forecasts, 2014 - 2025 (USD Billion)
4.3 Allograft
4.3.1 Allograft market estimates and forecasts, 2014 - 2025 (USD Billion)
4.4 Bone Morphogenetic Protein (BMP)
4.4.1 BMP market estimates and forecasts, 2014 - 2025 (USD Billion)
4.5 Viscosupplementation
4.5.1 Viscosupplementation market estimates and forecasts, 2014 - 2025 (USD Billion)
4.6 Synthetic Bone Substitutes
4.6.1 Synthetic bone substitutes market estimates and forecasts, 2014 - 2025 (USD Billion)
4.7 Stem Cell Therapy
4.7.1 Stem cell therapy market estimates and forecasts, 2014 - 2025 (USD Billion)
Chapter 5 Orthobiologics Market: Application Estimates & Trend Analysis
5.1 Orthobiologics market: Application movement analysis
5.2 Spinal Fusion
5.2.1 Spinal fusion market estimates and forecasts, 2014 - 2025 (USD Billion)
5.3 Trauma Repair
5.3.1 Trauma repair market estimates and forecasts, 2014 - 2025 (USD Billion)
5.4 Reconstructive Surgery
5.4.1 Reconstructive surgery market estimates and forecasts, 2014 - 2025 (USD Billion)
Chapter 6 Orthobiologics Market: End-use Estimates & Trend Analysis
6.1 Orthobiologics market: End-use movement analysis
6.2 Hospitals
6.2.1 Hospitals market estimates and forecasts, 2014 - 2025 (USD Billion)
6.3 Orthopedic Clinics
6.3.1 Orthopedic clinics market estimates and forecasts, 2014 - 2025 (USD Billion)
Chapter 7 Orthobiologics: Regional Estimates & Trend Analysis, by Product, Application & End-use
7.1 Orthobiologics market shares by region, 2015 & 2024
7.2 North America
7.2.1 North America orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.2.2 U.S.
7.2.2.1 U.S. orthobiologics market estimates and forecasts, 2014 - 2025(USD Billion)
7.2.3 Canada
7.2.3.1 Canada orthobiologics market estimates and forecasts, 2014 - 2025(USD Billion)
7.3 Europe
7.3.1 Europe orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.3.2 Germany
7.3.2.1 Germany orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.3.3 UK
7.3.3.1 UK orthobiologics market estimates and forecasts, 2014 - 2025(USD Billion)
7.4 Asia Pacific
7.4.1 Asia Pacific orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.4.2 Japan
7.4.2.1 Japan orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.4.3 China
7.4.3.1 China orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.4.4 India
7.4.4.1 India orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.5 Latin America
7.5.1 Latin America orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.5.2 Brazil
7.5.2.1 Brazil orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.5.3 Mexico
7.5.3.1 Mexico orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.6 MEA
7.6.1 MEA orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
7.6.2 South Africa
7.6.2.1 South Africa orthobiologics market estimates and forecasts, 2014 - 2025 (USD Billion)
Chapter 8 Competitive Landscape
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company Profiles
8.3.1 Bone Biologics, Corp.
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Medtronic
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Bioventus LLC
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Pioneer Surgical Technology
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 Smith & Nephew plc
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Stryker Corporation
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 DePuy Synthes, Inc.
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 Genzyme
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 Osiris Therapeutics, Inc.
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Globus Medical
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
8.3.11 Wright Medical Technology
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives
8.3.12 Orthofix, Inc.
8.3.12.1 Company Overview
8.3.12.2 Financial Performance
8.3.12.3 Product Benchmarking
8.3.12.4 Strategic Initiatives
8.3.13 NuVasive, Inc.
8.3.13.1 Company Overview
8.3.13.2 Financial Performance
8.3.13.3 Product Benchmarking
8.3.13.4 Strategic Initiatives
8.3.14 Zimmer Biomet
8.3.14.1 Company Overview
8.3.14.2 Financial Performance
8.3.14.3 Product Benchmarking
8.3.14.4 Strategic Initiatives
8.3.15 Anthrex
8.3.15.1 Company Overview
8.3.15.2 Financial Performance
8.3.15.3 Product Benchmarking
8.3.15.4 Strategic Initiatives